Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6959950 | 0.99 | SMN1; SMN2 (0.45) | SMN1; SMN2CHRM1CYP1A2CD274PDCD1 | |
| SCHEMBL5494553 | 0.88 | CHRM1 (0.46) | SMN1; SMN2CHRM1 | |
| SCHEMBL6967684 | 0.88 | CHRM1 (0.46) | SMN1; SMN2CHRM1 | |
| SCHEMBL6966900 | 0.88 | CHRM1 (0.46) | SMN1; SMN2CHRM1 | |
| Hydrochloric Acid SCHEMBL6970333 | 0.87 | SLC6A1 (0.47) | SMN1; SMN2CHRM1 | |
| Hydrochloric Acid SCHEMBL6961948 | 0.87 | SLC6A1 (0.47) | SMN1; SMN2CHRM1 | |
| Hydrochloric Acid SCHEMBL6969081 | 0.87 | SLC6A1 (0.47) | SMN1; SMN2CHRM1 | |
| SCHEMBL5501023 | 0.84 | CHRM1 (0.42) | CHRM1CYP1A2 | |
| SCHEMBL5498207 | 0.84 | CHRM1 (0.42) | CHRM1CYP1A2 | |
| SCHEMBL8500525 | 0.84 | KDM4E (0.51) | SMN1; SMN2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934313-B1 | N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS | NOVO NORDISK AS (DK) | 2003-05-14 | — | — | EP | claimed |
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | claimed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | claimed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | claimed |
| US-6004983-A | ANALGESICS; ANTIINFLAMMATORY, ANTIARTHRITIC AND ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DE) | 1999-12-21 | — | — | US | claimed |
| EP-0934313-A1 | N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1999-08-11 | — | — | EP | claimed |
| WO-1998015549-A1 | N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-04-16 | — | — | WO | claimed |
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | disclosed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | disclosed |
| US-6004983-A | ANALGESICS; ANTIINFLAMMATORY, ANTIARTHRITIC AND ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DE) | 1999-12-21 | — | — | US | disclosed |
| EP-0934313-A1 | N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998015549-A1 | N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | VEGFA, KDR, FLT4 | SMN1; SMN2 1377/4885CHRM1 4192/4885CYP1A2 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.